FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF REMICADE^® FOR TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

Janssen Biotech, Inc.

© Janssen Biotech, Inc. 2011. All Rights Reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy,
Safe Harbor Privacy Policy. This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. Capitalized product names are trademarks of Janssen Biotech, Inc. This information is intended for use by our customers, patients and healthcare professionals in the United States only. Janssen Biotech, Inc. recognizes that the internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

This page was last modified on: May 09 2012 at 13:04:50 EDT

FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF REMICADE® FOR TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

Press & Media

FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF REMICADE^® FOR TREATMENT OF PEDIATRIC ULCERATIVE COLITIS